Literature DB >> 7190295

Effectiveness of lofexidine in blocking morphine-withdrawal signs in the rat.

G T Shearman, H Lal, R C Ursillo.   

Abstract

Discontinuation of chronic morphine infusion in rats resulted in the reliable occurrence of withdrawal body shakes. This sign of narcotic withdrawal was dose-dependently reduced by lofexidine (0.04-0.64 mg/kg) and clonidine (0.01-0.16 mg/kg). As with clonidine, the activity of lofexidine was not prevented by naloxone (5 mg/kg). In addition, diarrhea induced by naloxone (5 mg/kg) in morphine dependent rats was also prevented by lofexidine or clonidine pretreatment. These data suggest that lofexidine, like clonidine, may reduce the narcotic withdrawal syndrome in humans.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7190295     DOI: 10.1016/0091-3057(80)90191-4

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  5 in total

1.  Differential effects of acute and chronic treatment with the α2-adrenergic agonist, lofexidine, on cocaine self-administration in rhesus monkeys.

Authors:  Stephen J Kohut; Peter A Fivel; Nancy K Mello
Journal:  Drug Alcohol Depend       Date:  2013-08-11       Impact factor: 4.492

2.  Similar decrease in spontaneous morphine abstinence by methadone and RB 101, an inhibitor of enkephalin catabolism.

Authors:  F Ruiz; M C Fournié-Zaluski; B P Roques; R Maldonado
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

3.  Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings.

Authors:  Rajita Sinha; Anne Kimmerling; Cheryl Doebrick; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2006-11-29       Impact factor: 4.530

4.  Effects of morphine, clonidine, and intensity change on electric-shock discrimination.

Authors:  R F Genovese; L A Dykstra
Journal:  J Exp Anal Behav       Date:  1984-05       Impact factor: 2.468

5.  A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.

Authors:  Elmer Yu; Karen Miotto; Evaristo Akerele; Ann Montgomery; Ahmed Elkashef; Robert Walsh; Ivan Montoya; Marian W Fischman; Joseph Collins; Frances McSherry; Kathy Boardman; David K Davies; Charles P O'Brien; Walter Ling; Herbert Kleber; Barbara H Herman
Journal:  Drug Alcohol Depend       Date:  2008-05-27       Impact factor: 4.492

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.